Table 2.
Eligibility, baseline use at admission, recommended new prescriptions, prescription at discharge, and actual increase for individual medication
| Medication | Eligible, n (of all patients, %) | Use prior to admission, n (of eligible patients, %) | Newly recommended, n (of eligible patients, %) | Total Prescribed at discharge*, n (of eligible patients, %) | Newly prescribed at discharge, n (of newly recommended for patients, %) |
|---|---|---|---|---|---|
| ACEI/ARB | 51,847 (32.62) | 23,059 (44.48) | 28,788 (55.52) | 48,842 (94.20) | 26,257 (91.21) |
| βB | 63,878 (40.19) | 31,595 (49.46) | 32,283 (50.54) | 61,532 (96.33) | 30370 (94.07) |
| Aldosterone antagonist |
43,780 (27.55) | 5,532 (12.64) | 38,248 (87.36) | 15,353 (35.07) | 10400 (27.19) |
| H/ISDN | 14,742 (9.28) | 1,015 (6.89) | 13,727 (93.11) | 3,480 (23.61) | 2596 (18.91) |
| Warfarin | 49,304 (31.02) | 20,709 (42.00) | 28,595 (58.00) | 36,061 (73.14) | 16133 (56.42) |
ACEI/ARB indicates angiotensin converting enzyme inhibitors/angiotensin receptor blockers; βB, beta-blockers; and H/ISDN, hydralazine/isosorbide dinitrate.
*
Includes continuing prescription (with use prior to admission) and newly prescribed.